Comparison between pathogen directed antibiotic treatment and empiri cal broad spectrum antibiotic treatment in patients with community acquired pneumonia.

Slides:



Advertisements
Similar presentations
Antimicrobial Prescribing in the Management of COPD
Advertisements

Chest Infections Lawrence Pike.
Yong Lee ICU Registrar John Hunter Hospital
Prevention of Ventilator Associated Pneumonia
Severity of Disease, Radiographic Presentation, and Outcomes in Ten Adult Patients with Mycoplasma pneumoniae Pneumonia: Results from the Rapid Empiric.
Community Acquired Pneumonia Guidelines 2011 Top 11 Recommendations Michael H. Kim.
The Evaluation of the Effectiveness of the Trivalent Influenza Vaccine for the Prevention of Hospitalizations Due to Influenza Pneumonia; Results from.
PNEUMONIA Fadi J. Zaben RN MSN.
Prof. Dr. Bilun Gemicioğlu
Pneumonia Why do we need to know about it? Long recognized as a major cause of death, Pneumonia has been studied intensively since late 1800s. Despite.
Community Acquired Pneumonia Dr Vincent Ioos Medical Intensive Care Unit Pakistan Institute of Medical Sciences.
COMMUNITY ACQUIRED PNEUMONIA…..AN OVERVIEW DR E. A. ODEGHE.
Ventilator-Associated Pneumonia. Introduction Definition 48 hours after intubation mechanically ventilated No clinical evidence of pneumonia prior to.
Lower Respiratory Tract Infection. Pneumonia Common with high morbidity and mortality rates. Acute respiratory infection with focal chest signs and radiographic.
Bacterial Pneumonia Sung Chul Hwang, M.D. Dept. of Pulmonary and Critical Care Medicine Ajou University School of Medicine.
Lower Respiratory Tract Infections in Children Abdelaziz Elamin Professor of Child Health University of Khartoum Sudan.
Cost-Conscious Care Presentation Follow-up Chest X-Ray in Patients Admitted for Community Acquired Pneumonia Huy Tran, PGY-2 12/12/2013.
Dr. Paramita Sengupta Department Of Community Medicine Christian Medical College Ludhiana Co-authors: Ragini Mann, Rohit Theodore, A I Benjamin Risk factors.
Top 5 Papers in Infectious Diseases Pharmacotherapy: A Review of 2013 for the General Practitioner Sharanie V. Sims, Pharm.D., BCPS (AQ-ID) Infectious.
Sarah Struthers, MD March 19, 2015
The Importance of Viral Etiology in Hospitalized Patients with Community Acquired Pneumonia in Jefferson County Martin Gnoni MD, Swetha Kadali, MD, Jorge.
Respiratory Tract Infections
Insert Program or Hospital Logo Introduction The Respiratory Syncytial virus (RSV) was discovered in 1956 and has been since recognized as one of the most.
Plans for Diagnosis of Community Acquired Pneumonia.
PRESENTER: HALIMATUL NADIA M HASHIM SUPERVISOR: DR NIK AZMAN NIK ADIB.
Chapter 22 Pulmonary Infections. Mosby items and derived items © 2009 by Mosby, Inc., an affiliate of Elsevier Inc. 2 Objectives  State the incidence.
Serum procalcitonin and C-reactive protein in children with community- acquired pneumonia K.Gogvadze, I.Guramishvili, I.Chkhaidze, K.Nemsadze, T.Maglakelidze.
Part I BACKGROUND VENTILATOR ASSOCIATED PNEUMONIA.
TABLE Common Causes of Community-Acquired Pneumonia in Patients Who Do Not Require Hospitalization* Mycoplasma pneumoniae Streptococcus pneumoniae.
Pneumonia Dr. Meg-angela Christi Amores. Definition infection of the pulmonary parenchyma often misdiagnosed, mistreated, and underestimated community-acquired.
The study of Pathogens causing Community Acquired Pneumonia in hematological malignancy patients comparing to general patients who hospitalized in Naresuan.
Incidence of hospitalisations in both groups Incidence of documented infections Abstract Problem statement: Patients on cancer chemotherapy are at substantial.
This lecture was conducted during the Nephrology Unit Grand Ground by Medical Student under Nephrology Division under the supervision and administration.
Bacterial Pneumonia.
Community Acquired Pneumonia in the Emergency Department (ED) Emergency Department Nurses & Physicians Dr. Mark Cichon, Director; Bridget Gaughan, Manager.
Pneumonia Egan’s Chapter 22. Mosby items and derived items © 2009 by Mosby, Inc., an affiliate of Elsevier Inc. 2 Introduction Infection involving the.
Hospital Acquired Pneumonia(HAP): is defined as a pneumonia which occurs after 48 hours of admission to hospital. Hospital Acquired Pneumonia(HAP): is.
Afebrile Infants With UTI and the Risk for Bacteraemia Journal Club Sheffield Children’s Hospital Naheed Maher 7 th January 2015.
Mini BAL v/s Bronchoscopic BAL PROF. PRADYUT WAGHRAY MD (CHEST), DTCD, FCCP (USA),D.SC(PULM. MEDICINE) HEAD OF DEPT. OF PULMONARY MEDICINE S.V.S MEDICAL.
1 EFFICACY OF SHORT COURSE AMOXICILLIN FOR NON-SEVERE PNEUMONIA IN CHILDREN (Hazir T*, Latif E*, Qazi S** AND MASCOT Study Group) *Children’s Hospital,
Risk factors for severe disease from pandemic (H1N1) 2009 virus infection reported to date are considered similar to those risk factors identified for.
1 Recent Advances in Provision of Primary Care in the Public Sector: Is 3 Days of Oral Antibiotic Therapy Enough for Treatment of Ambulatory Pneumonia?
R3 정수웅. Introduction Community-acquired pneumonia − Leading infectious cause of death in developed countries − The mortality in patients with treatment.
Diamantis P. Kofteridis, Christina Alexopoulou, Antonios Valachis, Sofia Maraki, Dimitra Dimopoulou Clinical Infectious Diseases 2010; 51(11):1238–1244.
Community Acquired Pneumonia Peter Valenzuela, MD, MBA, FAAFP Assistant Dean for Clinical Affairs Assistant Professor/Dept. of Family Medicine.
폐렴으로 오인할 수 있는 폐렴 외 질환 호흡기 내과 R3 최 문 찬.
Community-Acquired Pneumonia Richard G. Wunderink, M.D., and Grant W. Waterer, M.B., B.S., Ph.D. N Engl J Med 2014;370: R3 김선혜 /Prof. 박명재 1.
Tigecycline use in serious nosocomial infections: a drug use evaluation Matteo Bassetti*, Laura Nicolini, Ernestina Repetto, Elda Righi, Valerio Del Bono,
PROSPECTIVE COHORT STUDY OF ACUTE PYELONEPHRITIS IN ADULTS: SAFETY OF TRIAGE TOWARDS HOME BASED ORAL ANTIMICROBIAL TREATMENT C. VAN NIEUWKOOP A,*, J.W.
Depart. Of Pulmonology and Critical Care Medicine R4 백승숙.
Antibiotics in Addition to Systemic Corticosteroids for Acute Exacerbations of Chronic Obstructive Pulmonary Disease Johannes M.A. Daniels; Dominic snijders;
Community Acquired Pneumonia. Definitions Community acquired pneumonia (CAP) – Infection of the lung parenchyma in a person who is not hospitalized or.
PNEUMONIA BY: NICOLE STEVENS.
Time for first antibiotic dose is not predictive for the early clinical failure of moderate–severe community-acquired pneumonia Eur J Clin Microbial Infect.
APIC Chapter 13 Journal Club March 16, 2015 Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults NEJM – July 30, :5 Presented.
Community Acquired Pneumonia
Pneumonia.
Infective endocarditis
Pneumonia Salutations:
Community Acquired Pneumonia
Pneumonia Dr. Gerrard Uy.
Dr Asmaa fathy abdellah hassan
Antibiotics sensitivity of microorganism causing nosocomial infections
PHARMACOTHERAPY III PHCY 510
CAP Therapy Babak Sayad Associate Professor of Infectious Diseases
بنام خداوند جان و خرد بنام خداوند جان و خرد.
G. Höffken  Clinical Microbiology and Infection 
Ordering Sputum Cultures in Community Acquired Pneumonia
Community Acquired Pneumonia
Presentation transcript:

Comparison between pathogen directed antibiotic treatment and empiri cal broad spectrum antibiotic treatment in patients with community acquired pneumonia : a prospective randomised study M M van der Eerden, F Vlaspolder, C S de Graaff, T Groot, W Bronsveld, H M Jansen, W G Boersma Thorax 2005;60:672–678.

Background Community acquired pneumonia (CAP) common and serious illness Main advantage of pathogen directed treatment : careful use of antibiotics : reduction in adverse events and antimicrobial resistance American Thoracic Society (ATS) guidelines : primarily consensus based : not been prospectively validated and compared with other regimen(s) in a clinical setting → prospective randomised study → pathogen directed approach compared with empirical broad spectrum antibiotics according to the ATS guidelines of 1993

METHODS prospective randomised study December 1998 and November 2000 in the Departments of Pulmonary Diseases and Internal Medicine at the Medical Centre Alkmaar Patients (1) age18 years or over (2) one or more of symptoms suggesting CAP: fever (>38.0˚C), dyspnoea, coughing (with or without expectoration of sputum), chest pain (3) new consolidation(s) on the chest radiograph Exclusion criteria severe immunosuppression (HIV infection, high dose of immunosuppressive agents such as prednisone >35 mg/day, chemotherapy), malignancy, pregnancy or breast feeding, severe allergy to antibiotics, obstruction pneumonia, pneumonia within 8 days of hospital discharge.

Study design 2 treatment groups by cards in sealed envelopes empirical antibiotic treatment (EAT) group Beta-lactam/b-lactamase inhibitor plus erythromycin IV Ceftazidime and erythromycin IV : ICU pathogen directed treatment (PDT) group

Outcome Clinical efficacy primarily determined LOS -No criteria for discharge -not informed about LOS as an outcome parameter Secondary outcome parameters (1) therapeutic failure -early failure : not improved symptoms of pneumonia within 72 hours of antibiotic treatment and persisted or progressed -late failure : following an initially good response on antibiotic treatment, symptoms of pneumonia returned after 72 hours of admission or died before the 30 day follow up (2) 30 day mortality, duration of iv antibiotic treatment, total duration of antibiotic treatment, resolution of fever, presence of adverse events, and quality of life

Microbiological investigations sputum specimen for Gram staining, semi-quantitative culture, and S pneumoniae antigen detection testing three sets of blood cultures if clinical symptoms suggested, urine sample for L. pneumophila serogroup 1 antigen detection bronchoalveolar lavage (BAL) specimen and protected specimen brush (PSB) : when patients did not expectorate sputum within 24 hours of admission Thoracentesis : when pleural fluid was present Blood samples for serology on days 1 and 14 for the detection of antibodies to Mycoplasma pneumoniae, Chlamydia pneumoniae, L pneumophila serogroup 1–7, influenza A and B virus, parainfluenza virus 1–3, respiratory syncytial virus (RSV), and adenovirus S pneumoniae antigen in the urine samples

Definitive aetiology (1) identification of etiological agent in blood or pleural fluid (2) L. pneumophila spp antigen in the urine (3) S pneumoniae antigen in pleural fluid (4) a threefold increase in antibody titre of L pneumophila serogroup 1–7, M pneumoniae, C pneumoniae, influenza A and B, parainfluenza virus 1–3, RSV or adenovirus Presumptive aetiology (1) a positive sputum, BAL or PSB culture by semi-quantitative methods (2) detection of S pneumoniae antigen in urine or sputum, BAL or PSB specimen (3) IgM titre of >17 U/ml for M pneumoniae. Statistical analysis

RESULTS

P=0.03 Hospitalized P=0.03 > <

DISCUSSION In this prospective randomised study, no significant difference in outcome between a PDT and EAT Only adverse events, not clinically significant, occurred more often in the EAT group than PDT group (p,0.001) in this study, no criteria for discharge were given -decision to discharge was based on clinical judgement Patients in the EAT group were significantly older than those in the PDT group (p=0.03) atypical bacterial pathogens ( L pneumophila, M pneumoniae and C pneumoniae), cannot be identified by conventional microbiological methods during the first days of treatment

Limitations in this study for logistical reasons, it was not possible to perform a double blind, randomised study the study was powered according to LOS and not according to mortality antibiotic treatment according to 1993 ATS guidelines for EAT. New guidelines in 2001 are not essentially different with the exception of ICU patients admission of low risk patients (risk class I–II) In conclusion Empirical approach with broad spectrum antibiotics has comparable efficacy to a pathogen directed approach